403 related articles for article (PubMed ID: 16934544)
1. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
Rogers A; Clowes JA; Pereda CA; Eastell R
Bone; 2007 Jan; 40(1):105-10. PubMed ID: 16934544
[TBL] [Abstract][Full Text] [Related]
2. Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood.
Rogers A; Eastell R
J Bone Miner Res; 1998 Oct; 13(10):1577-86. PubMed ID: 9783546
[TBL] [Abstract][Full Text] [Related]
3. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
4. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
[TBL] [Abstract][Full Text] [Related]
5. Effects of estrogen on temporal expressions of IL-1beta and IL-1ra in rat organotypic hippocampal slices exposed to oxygen-glucose deprivation.
Choi JS; Kim SJ; Shin JA; Lee KE; Park EM
Neurosci Lett; 2008 Jun; 438(2):233-7. PubMed ID: 18455872
[TBL] [Abstract][Full Text] [Related]
6. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
[TBL] [Abstract][Full Text] [Related]
7. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
8. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
9. Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling.
Pineda B; Hermenegildo C; Tarín JJ; Cano A; García-Pérez MÁ
Menopause; 2012 Mar; 19(3):319-27. PubMed ID: 22067277
[TBL] [Abstract][Full Text] [Related]
10. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
[TBL] [Abstract][Full Text] [Related]
11. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
12. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
13. Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures.
Ramalho AC; Couttet P; Baudoin C; Morieux C; Graulet AM; de Vernejoul MC; Cohen-Solal ME
Eur Cytokine Netw; 2002; 13(1):39-45. PubMed ID: 11956019
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
16. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
D'Amelio P; Muratore M; Tinelli F; Tamone C; Cosentino L; Quarta E; Calcagnile F; Carlo Isaia G
Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596
[TBL] [Abstract][Full Text] [Related]
17. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
18. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation.
Riyazi N; Slagboom E; de Craen AJ; Meulenbelt I; Houwing-Duistermaat JJ; Kroon HM; van Schaardenburg D; Rosendaal FR; Breedveld FC; Huizinga TW; Kloppenburg M
Arthritis Rheum; 2005 May; 52(5):1443-50. PubMed ID: 15880595
[TBL] [Abstract][Full Text] [Related]
19. 17beta-estradiol and progesterone do not influence the production of cytokines from lipopolysaccharide-stimulated monocytes in humans.
Bouman A; Schipper M; Heineman MJ; Faas M
Fertil Steril; 2004 Oct; 82 Suppl 3():1212-9. PubMed ID: 15474098
[TBL] [Abstract][Full Text] [Related]
20. Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial.
Kumru S; Yildiz FM; Godekmerdan A; Kutlu S; Yilmaz B; Gurates B
Arch Gynecol Obstet; 2008 Jun; 277(6):489-93. PubMed ID: 18066566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
